春季银行将在HepDART 2019上展示其针对乙型肝炎的新型嵌合反

StephenW

Spring Bank to Present Data on its Novel Chimeric Antisense Oligonucleotide Compounds for Hepatitis B at HepDART 2019

HOPKINTON, Mass., Dec. 09, 2019 (GLOBE NEWSWIRE)-Spring Bank Pharmaceuticals, Inc. (SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced two hepatitis B virus (HBV) poster presentations at HepDART 2019 being held December 8-12, 2019 in Kauai, Hawaii.

"We are excited to present impressive data on our chimeric antisense oligonucleotide (CASO) program in HBV, including our preclinical candidate, SB 527, at HepDART 2019," commented Dr. Radhakrishnan Iyer, Co-Founder and Chief Scientific Officer of Spring Bank Pharmaceuticals . "Our CASO compounds incorporate the unique feature of having an antisense oligonucleotide linked to an immunomodulator in the same molecule. They are designed to achieve simultaneous HBV gene silencing, to inhibit the production of HBV DNA and all HBV proteins, and activation of innate and adaptive immunity for viral clearance. "Dr. Iyer continued," The data generated to date for SB 527 in non-clinical models demonstrate that our CASOs potently inhibit the production of HBV DNA, as well as HBsAg and HBeAg, the key viral proteins associated with HBV replication. We continue to advance the SB 527 program with the goal of developing a “triplet” therapeutic modality (antisense + immunomodulator + nucleos (t) ide). We believe that the inclusion of an immunomodulator in a triplet therapy regimen provides greater potential for a durable response, increasing the likelihood of achieving a functional cure. "

Spring Bank is developing its CASOs for potential use in the high viral burden chronic HBV patient population as part of a triple therapy regimen, which would include SB 527 plus inarigivir plus a nucleos (t) ide analog. Spring Bank is working in tandem with the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to evaluate Spring Bank's CASOs in the HBV mouse model, a well-established preclinical model to assess compound efficacy. Based on the results of these studies, the company plans to conduct IND-enabling toxicology studies in the first half of 2020 with the potential to be IND / CTA-ready in the latter half of 2020.

Presentations on Tuesday, December 10, 2019, from 3:30 – 5:00 (HST), include:

Poster Presentation # P14

Title: "Antisense Oligonucleotide Linked to an Immunomodulatory Dinucleotide are Highly Potent Anti-HBV Agents," by Dr. Lakshmi Bhagat, Discovery Group Leader – Immunology

Summary: Spring Bank ’s lead CASOs potently inhibit HBV DNA, HBsAg and HBeAg via a gene silencing mechanism as well as the intracellular release of an immunomodulator from the CASOs.

Poster Presentation # P5

Title: "The Anti-HBV Dinucleotide Inarigivir is a Novel RIG-I Agonist – MOA Studies," by Dr. Radhakrishnan Iyer, Co-Founder and Chief Scientific Officer

Summary: Preclinical results demonstrate that inarigivir activates the innate immune receptor RIG-I to produce interferons and cytokines for antiviral defense. These preclinical results further validate the mechanism of action and the observed antiviral efficacy of inarigivir in HBV patients.

Following these presentations, the posters will be available on the Publications page of the company ’s website.

StephenW

春季银行将在HepDART 2019上展示其针对乙型肝炎的新型嵌合反义寡核苷酸化合物的数据

马萨诸塞州霍普金顿，2019年12月9日（全球新闻）-临床阶段生物制药公司Spring Bank Pharmaceuticals，Inc.（SBPH）是一家临床阶段的生物制药公司，正在开发用于治疗病毒感染，炎性疾病和某些癌症的新型疗法，今天宣布了两项在2019年12月8日至12日在夏威夷考艾岛举行的HepDART 2019上，乙型肝炎病毒（HBV）海报展示。

“我们很高兴在HepDART 2019上展示有关HBV的嵌合反义寡核苷酸（CASO）程序的令人印象深刻的数据，包括我们的临床前候选药物SB 527，” Spring Bank Pharmaceuticals联合创始人兼首席科学官Radhakrishnan Iyer博士评论道。 。 “我们的CASO化合物具有独特的功能，即在同一分子中具有与免疫调节剂相连的反义寡核苷酸。它们旨在实现同时HBV基因沉默，抑制HBV DNA和所有HBV蛋白的产生以及固有和适应性的激活。清除病毒的免疫力。 Iyer继续说道，“迄今为止，在非临床模型中为SB 527生成的数据表明，我们的CASO可以有效抑制HBV DNA以及与HBV复制有关的关键病毒蛋白HBsAg和HBeAg的产生。 SB 527计划旨在开发一种“三联体”治疗方式（反义+免疫调节剂+核苷（t）ide），我们认为在三联体治疗方案中加入免疫调节剂可提供更大的持久应答潜力，从而增加了可能性实现功能性治愈。”

春季银行正在开发其CASO，作为三联疗法方案的一部分，可在高病毒负担的慢性HBV患者人群中潜在使用，其中包括SB 527加inarigivir加一个核苷酸（t）类似物。春季银行正在与美国国立卫生研究院下属的国家过敏和传染病研究所合作，以评估HBV小鼠模型中春季银行的CASO，后者是一种建立完善的临床前模型，用于评估复合疗效。根据这些研究的结果，该公司计划在2020年上半年进行支持IND的毒理学研究，并有可能在2020年下半年准备IND / CTA。

2019年12月10日（星期二）3:30 – 5:00（HST）的演讲包括：

海报展示＃P14

题目：“与免疫调节性二核苷酸连接的反义寡核苷酸是高度有效的抗HBV剂，”发现组负责人-免疫学专家Lakshmi Bhagat博士

简介：春季银行的主要CASO通过基因沉默机制以及从CASO中向细胞内释放免疫调节剂，有效抑制HBV DNA，HBsAg和HBeAg。

海报展示＃P5

标题：“抗HBV二核苷酸依那吉韦是一种新颖的RIG-I激动剂-MOA研究”，联合创始人兼首席科学官Radhakrishnan Iyer博士

简介：临床前结果表明，依那吉韦可以激活先天性免疫受体RIG-I产生干扰素和细胞因子，从而发挥抗病毒防御作用。这些临床前结果进一步验证了inarigivir在HBV患者中的作用机理和观察到的抗病毒效力。

在这些演示之后，海报将在公司网站的“出版物”页面上提供。

齐欢畅

马克

windu

茄子